Pfizer forecasts 2016 revenue, earnings below estimates

(Reuters) - U.S. drugmaker Pfizer Inc , which is in the process of buying Botox-maker Allergan Plc for $160 billion, forecast 2016 revenue and earnings below analysts' estimates, citing generic competition and a strong dollar. The company said it expects reported revenue of $49 billion-$51 billion for the full year and adjusted earnings of $2.20-$2.30 per share. Analysts on average were expecting revenue of $52.49 billion and earnings of $2.36 per share.